Crispr Theraptc (CRSP) Director Kurt Von Emster Sells 69,859 Shares

Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 69,859 shares of the business’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $16.84, for a total transaction of $1,176,425.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.56, for a total transaction of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.26, for a total transaction of $69,170.04.
  • On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.90, for a total transaction of $730,113.80.
  • On Tuesday, June 27th, Kurt Von Emster sold 81,435 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.08, for a total transaction of $1,390,909.80.
  • On Friday, June 23rd, Kurt Von Emster sold 32,368 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.23, for a total transaction of $525,332.64.

Crispr Theraptc (NASDAQ CRSP) traded up 0.65% on Monday, hitting $17.10. 72,054 shares of the stock traded hands. The firm’s 50 day moving average is $15.38 and its 200 day moving average is $18.28. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The stock’s market cap is $683.95 million.

Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.06. The business had revenue of $2.70 million during the quarter. Equities analysts anticipate that Crispr Theraptc will post ($2.42) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Crispr Theraptc (CRSP) Director Kurt Von Emster Sells 69,859 Shares” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://sportsperspectives.com/2017/07/17/crispr-theraptc-crsp-director-kurt-von-emster-sells-69859-shares.html.

A number of hedge funds have recently modified their holdings of the company. Credit Suisse AG acquired a new stake in shares of Crispr Theraptc during the first quarter valued at $1,742,000. Paulson & CO. Inc. acquired a new stake in shares of Crispr Theraptc during the first quarter valued at $1,099,000. Monashee Investment Management LLC boosted its stake in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the period. IHT Wealth Management LLC acquired a new stake in shares of Crispr Theraptc during the first quarter valued at $110,000. Finally, Wellington Management Group LLP boosted its stake in shares of Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the period. Institutional investors and hedge funds own 24.07% of the company’s stock.

A number of research analysts have weighed in on the stock. Cann assumed coverage on shares of Crispr Theraptc in a research report on Monday. They set a “market perform” rating for the company. Chardan Capital assumed coverage on shares of Crispr Theraptc in a research report on Monday, March 27th. They set a “buy” rating and a $23.50 target price for the company. Finally, SunTrust Banks, Inc. assumed coverage on shares of Crispr Theraptc in a research report on Thursday. They set a “hold” rating and a $16.00 target price for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Crispr Theraptc has a consensus rating of “Buy” and an average target price of $21.92.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply